Abstract
Fibrate peroxisome proliferator-activated receptor (PPAR)-α ligands are mainly used as hypolipidemic drugs. But this commentary highlights their potential in treating insulin resistance, dyslipidemia, and hypertension and in preventing diabetic nephropathy, inflammation, and cardiovascular disease. Because diabetes is a major contributor to chronic kidney disease and cardiovascular disease, PPAR-α agonists may provide greater opportunities for hitting multiple targets in this complex metabolic disease. © 2006 International Society of Nephrology.
Cite
CITATION STYLE
Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2006). The PPARα ligand fenofibrate: Meeting multiple targets in diabetic nephropathy. Kidney International. Nature Publishing Group. https://doi.org/10.1038/sj.ki.5000180
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
